Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4405 ARTÍCULOS , VIENDO DEL 1081 AL 1095

Secondary parkinsonism in a patient of psychogenic polydipsia

Pal R, Das L, Dutta P, Bhansali A.

BMJ Case Rep. 2017 Apr 26;2017:bcr2016218722. doi: 10.1136/bcr-2016-218722.

Preventing Parkinson disease by vagotomy: Fact or fiction?

Borghammer P, Hamani C.

Neurology. 2017 May 23;88(21):1982-1983. doi: 10.1212/WNL.0000000000003969. Epub 2017 Apr 26.

Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study

Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, Shprecher DR, Davis C, Davis MD, Stamler D, Anderson KE.

Neurology. 2017 May 23;88(21):2003-2010. doi: 10.1212/WNL.0000000000003960. Epub 2017 Apr 26.

Control of mitochondrial biogenesis and function by the ubiquitin-proteasome system

Bragoszewski P, Turek M, Chacinska A.

Open Biol. 2017 Apr;7(4):170007. doi: 10.1098/rsob.170007.

Immunomodulatory effects of stem cells: Therapeutic option for neurodegenerative disorders

Caprnda M, Kubatka P, Gazdikova K, Gasparova I, Valentova V, Stollarova N, La Rocca G, Kobyliak N, Dragasek J, Mozos I, Prosecky R, Siniscalco D, Büsselberg D, Rodrigo L, Kruzliak P.

Biomed Pharmacother. 2017 Jul;91:60-69. doi: 10.1016/j.biopha.2017.04.034. Epub 2017 May 23.

Parkinsonism and high-intensity midbrain lesions on T2-weighted imaging in hepatic encephalopathy: a case report

Ishii N, Mochizuki H, Sakai K, Shiomi K, Nakazato M.

Neurol Sci. 2017 Aug;38(8):1547-1549. doi: 10.1007/s10072-017-2976-8. Epub 2017 Apr 27.

The measuring of substantia nigra hyperechogenicity in an Italian cohort of Parkinson disease patients: a case/control study (NOBIS Study)

Prati P, Bignamini A, Coppo L, Naldi A, Comi C, Cantello R, Gusmaroli G, Walter U.

J Neural Transm (Vienna). 2017 Jul;124(7):869-879. doi: 10.1007/s00702-017-1724-9. Epub 2017 Apr 27.

Steady-State Kinetics of α-Synuclein Ferrireductase Activity Identifies the Catalytically Competent Species

McDowall JS, Ntai I, Hake J, Whitley PR, Mason JM, Pudney CR, Brown DR.

Biochemistry. 2017 May 16;56(19):2497-2505. doi: 10.1021/acs.biochem.7b00257. Epub 2017 May 4.

Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease

Regidor I, Benita V, Del Álamo de Pedro M, Ley L, Martinez Castrillo JC.

Clin Neuropharmacol. 2017 May/Jun;40(3):103-107. doi: 10.1097/WNF.0000000000000216.

Cortical plasticity and levodopa-induced dyskinesias in Parkinson's disease: Connecting the dots in a multicomponent network

Rajan R, Popa T, Quartarone A, Ghilardi MF, Kishore A.

Clin Neurophysiol. 2017 Jun;128(6):992-999. doi: 10.1016/j.clinph.2017.03.043. Epub 2017 Apr 10.

Therapeutic implication of autophagy in neurodegenerative diseases

Rahman MA, Rhim H.

BMB Rep. 2017 Jul;50(7):345-354. doi: 10.5483/bmbrep.2017.50.7.069.

Old and new challenges in Parkinson's disease therapeutics

Pires AO, Teixeira FG, Mendes-Pinheiro B, Serra SC, Sousa N, Salgado AJ.

Prog Neurobiol. 2017 Sep;156:69-89. doi: 10.1016/j.pneurobio.2017.04.006. Epub 2017 Apr 27.

The neuroprotective effect of focused ultrasound: New perspectives on an old tool

Yulug B, Hanoglu L, Kilic E.

Brain Res Bull. 2017 May;131:199-206. doi: 10.1016/j.brainresbull.2017.04.015. Epub 2017 Apr 27.

Ablative surgery for Parkinson's disease: Is there still a role for pallidotomy in the deep brain stimulation era?

Spindola B, Leite MA, Orsini M, Fonoff E, Landeiro JA, Pessoa BL.

Clin Neurol Neurosurg. 2017 Jul;158:33-39. doi: 10.1016/j.clineuro.2017.04.018. Epub 2017 Apr 23.

DJ-1/PARK7: A New Therapeutic Target for Neurodegenerative Disorders

Hijioka M, Inden M, Yanagisawa D, Kitamura Y.

Biol Pharm Bull. 2017;40(5):548-552. doi: 10.1248/bpb.b16-01006.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias